Abstract
The introduction of novel agents, such as thalidomide, bortezomib, and lenalidomide, has altered the landscape of therapeutic options for multiple myeloma by offering new mechanisms for targeting this disease. Combinations of these agents, with each other and/or traditional chemotherapeutics, have vastly increased the treatment options for patients both frontline, and at relapse, providing higher response rates, and importantly, increasing median overall survival. In this review, we will discuss the use of these novel agents and their combinations in patients with relapsed and/or refractory multiple myeloma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 485-493 |
| Number of pages | 9 |
| Journal | Cancer Journal |
| Volume | 15 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 2009 |
Keywords
- Bortezomib
- Lenalidomide
- Multiple myeloma
- Novel agents
- Thalidomide
ASJC Scopus subject areas
- Oncology
- Cancer Research